Business Wire

AB InBev PureDraught™ Keg System Wins World Beverage Innovation Award

Share

AB InBev and its Global Innovation and Technology Center (GITEC) announced that PureDraught™, a revolutionary one-way polymer keg system, won a World Beverage Innovation Award for “Best Manufacturing/Processing Innovation.” The honor was awarded at the BrauBeviale 2019 trade fair in Nuremberg, Germany.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191118005495/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

PureDraught™ keeps beer fresher up to four times longer than a traditional steel keg and reduces the carbon footprint of shipping beer -- all while offering more versatility and variety for bar and restaurant owners. (Photo: Business Wire)

PureDraught™ keeps beer fresher up to four times longer than a traditional steel keg and reduces the carbon footprint of shipping beer -- all while offering more versatility and variety for bar and restaurant owners.

Using a custom-molded, double-walled, bottle-in-bottle polymer keg, PureDraught allows air or gas to be fed into the outer bottle, which keeps its shape and pushes the beer out of the inner bottle. This innovation prevents any air or dispense gas from touching the beer, allowing the beer to remain fresh for 30 days after being tapped instead of just a week.

In addition, PureDraught comes in 6L, 12L and 18L sizes rather than the standard 30L or larger steel keg size, allowing for more flexibility and less wasted product by bar and restaurant owners. The kegs can be stored and dispensed from upright or on their side on a shelf, making them more versatile.

“We are honored that our research and technological innovation for PureDraught has been recognized by the prestigious World Beverage Innovation Awards,” said Rodrigo Sozo, Vice President of AB InBev GITEC. “This is a validation of the hard work and passion of our team as they set out to develop a transformational innovation for draught beer, including superior quality, less carbon footprint and more variety of beers on tap. We are also excited about how the technology platform creates new consumer experiences for all types of occasions of draught beer consumption.”

There are no additional costs for a bar to use the PureDraught system or the beer in the one-way kegs, and in most markets, the system’s custom keg coupler is provided and connected to a bar’s existing beer and gas lines by AB InBev free of charge.

Currently, PureDraught is in use with AB InBev brands in more than eight countries, including the U.S., Mexico, Brazil, China, Italy, Japan and South Korea as well as additional areas of Europe and Africa, providing the best pour of brands like Stella Artois. For more information, including how to convert your establishment to PureDraught, visit https://puredraught.com/.

About AB InBev GITEC

The Global Innovation and Technology Center (GITEC) at AB InBev is the hub of innovation for the company, working across teams and the company’s more than 500 brands to develop new products, processes and technologies. Driven by a team of more than 120 passionate R&D talents from more than 20 countries, GITEC works to revolutionize packaging, make the brewing process more efficient and sustainable, create breakthroughs in how our beers are delivered and dispensed, and to offer new tasting and consumer experiences.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Shawn Malayter
Greenhouse Partners
872-267-2636
smalayter@greenhousepartners.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye